Be Biopharma Stock

be.bioHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $182.1MM

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Register To Buy and Sell Shares

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Be Biopharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Be Biopharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Brad Hartman
Chief People Officer
Rick Morgan
Chief Scientific Officer
Lea Hachigian
Co-Founder & VP of Strategy
Joanne Smith-Farrell
Chief Executive Officer
Krishnan Viswanadhan
President & Chief Operating Officer

Board Members

Steven Gillis
Arch Venture Partners

Frequently Asked Questions About Be Biopharma’s Stock

Can you buy Be Biopharma’s stock?
Be Biopharma is not publicly traded on NYSE or NASDAQ in the U.S. To buy Be Biopharma’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Be Biopharma’s stock?
Yes, you can sell stock of a private company like Be Biopharma. Forge can help you sell your Be Biopharma stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Be Biopharma’s stock price?
Be Biopharma is a privately held company and therefore does not have a public stock price. However, you may access Be Biopharma’s private market stock price with Forge Data.
What is Be Biopharma’s stock ticker symbol?
Be Biopharma does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.